GSK-3β-IN-28
GSK-3β inhibitor 28 is selective and non-competitivea glycogen synthase kinase-3β (GSK-3β) inhibitor with an IC50 of 14.82 nM. GSK-3β inhibitor 28 can upregulate the expression level of phosphorylated GSK-3β and downregulate the expression of p-NF-κB, P65, C-myc and Cyclin D1. GSK-3β inhibitor 28 can induce cells apoptosis, G1 phase arrest and inhibit migration. GSK-3β inhibitor 28 can be used for the research of cancer, such as colorectal cancer[1].
Product Specifications
UNSPSC
12352005
Target
Apoptosis; c-Myc; GSK-3; NF-κB
Related Pathways
Apoptosis; NF-κB; PI3K/Akt/mTOR; Stem Cell/Wnt
Field of Research
Cancer
Smiles
O=C(N1CCC2=CC=CC=C2)N(C3=CC4=C(N(C(C=C)=O)C=C4Cl)C=C3)SC1=O
Molecular Formula
C21H16ClN3O3S
Molecular Weight
425.89
References & Citations
[1]Xu J, et al. Design, synthesis, and biological evaluation of novel GSK-3β covalent inhibitors for cancer treatment. Bioorg Chem. 2025 Sep;164:108856.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
GSK-3β
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
